$20.0M
The London-based recruitment startup has secured backing from Creandum, Dig Ventures, and a roster of angel investors.
E
Episode1
Venture CapitalPortfolio
7
companies
Investment by month
By category
- AI/ML£17.0M
- Uncategorised£16.7M
- MedTech£6.3M
- FinTech£4.0M
- BioTech£2.5M
By location
- London£44.0M
- Cambridge£2.5M
Portfolio companies
A
AimBrain
AimBrain develops biometric authentication technology for financial services.
J&
Jack & Jill AI
Jack & Jill AI builds autonomous software agents to automate recruitment.
MediShout
MediShout provides a digital platform that unifies hospital helpdesks and medical suppliers.
Opteran
Opteran builds natural intelligence software to power machine autonomy.
Phasecraft
Phasecraft develops high performance algorithms to unlock the practical capabilities of quantum computers.
Presentient Technologies
Presentient Technologies builds software platforms for clinical trial analytics.
View all 7 companiesShow fewer
Team
PM
Paul McNabb
Managing Partner
Paul serves as managing partner at Episode1 and holds board roles across several technology companies. He brings venture capital experience from investments in firms such as Opteran and Webiny.
LinkedInRecent investments
£13.0M
Playground Global led the Series A round to support the firm in achieving practical quantum advantage.
"For all the advances that have been made in quantum hardware, and for all quantum computing’s promise, such progress could end up being for nothing if we can’t build the applications needed to make the technology truly useful. With our record-breaking algorithms and groundbreaking techniques, we are pushing the boundaries of what is possible in this space. With support from such a renowned deep-tech visionary as Playground, we think practical quantum advantage is achievable in years, not decades."
£4.3M
The seed round was led by Nickleby Capital with participation from KHP Ventures, Atomico Angels, and Episode1 Ventures.
"We founded MediShout to address the operational problems that prevent best patient care in hospitals,"
£2.0M
QVentures led the pre-seed round with backing from Episode1 and industry angels to support the Meristem platform.
"Clinical trials are to medicine what elections are to democracy; they are the definitive process behind every significant step forwards and how we reason about what is effective and safe and what is not."
£2.5M
The seed round was led by Episode1 with backing from Seedcamp, Cambridge Enterprise, and January Ventures to fund DNA testing kits and platform development.
"We urgently need more people contributing to medical science, but the gap between those wanting to take part and actually knowing how to is huge. The scientific community has long relied on time-starved doctors signposting patients to clinical trials which just isn’t an effective way to get decent levels of participation. The pandemic has added further challenges, as many patients with rare and chronic diseases are unable to safely leave home."
